Neutra Life Sciences Expands Clinical Research Network with New Family Medicine Partnership

Neutra Corp's wholly owned subsidiary, Neutra Life Sciences, has expanded its clinical research footprint by securing a new clinical trial site partnership with MediNet Family Care Clinic, which specializes in Internal Medicine and Family Medicine. This strategic move aligns with the company's ongoing mission to grow its site management organization and bring high-quality, community-based research opportunities to diverse patient populations. The expansion into family medicine represents a significant step in making clinical trials more accessible to broader demographic groups who often receive care through primary care settings.

Located in a high-traffic area near the border of Sugar Land and Houston, this Internal Medicine and Family Medicine site is led by an experienced research team with a strong background in conducting clinical trials and delivering consistent, quality data. The site is fully equipped to support a wide range of protocol designs, including Phase II and III studies focused on chronic conditions such as hypertension, diabetes, hyperlipidemia, and other prevalent therapeutic areas. This capability is particularly important given the growing prevalence of chronic diseases in the United States and the need for more representative clinical trial populations.

Sydney Jim, CEO of Neutra Corp, emphasized the strategic importance of this expansion, stating that the new partnership represents another important step in the company's long-term strategy to grow organically and provide sponsors and contract research organizations with efficient, responsive, and high-performing research sites. By expanding into Internal Medicine and Family Medicine, Neutra Life Sciences is furthering its ability to support diverse protocols while continuing to meet the highest standards of patient care and data integrity. This approach addresses the pharmaceutical industry's increasing demand for real-world evidence and community-based research settings.

The company also announced it has engaged a dedicated Investor Relations Firm to strengthen communication and transparency with shareholders and the broader investment community. This strategic move underscores the company's commitment to building lasting investor confidence, enhancing market visibility, and providing timely, accurate insights into the company's growth, performance, and strategic direction. Neutra Life Sciences continues to experience steady growth across multiple specialties, with plans to add additional therapeutic areas in the coming quarters. Each new site is carefully selected and supported to ensure optimal performance and alignment with sponsor and contract research organization expectations.

With this expansion, Neutra Life Sciences is preparing to launch a new Diabetic Foot Ulcer trial at one of its brand-new sites in Sugar Land, Texas, demonstrating the immediate practical application of the expanded network capabilities. The company maintains its corporate information at https://www.neutrainc.com while the subsidiary's operations can be followed through its dedicated platform. This growth in clinical research infrastructure comes at a critical time when the healthcare industry is placing increased emphasis on diversity in clinical trials and real-world evidence generation, positioning Neutra Life Sciences to capitalize on these emerging trends in pharmaceutical research and development.